# Campath in Chronic GVHD

> **NCT00495755** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 13 (actual)

## Conditions studied

- Chronic Graft-vs.-Host Disease

## Interventions

- **DRUG:** Alemtuzumab (Campath)

## Key facts

- **NCT ID:** NCT00495755
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2011-10
- **Final completion:** 2012-10
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2013-08-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00495755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00495755, "Campath in Chronic GVHD". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00495755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*